Drug Profile
Varlitinib - Array BioPharma/ASLAN Pharmaceuticals
Alternative Names: ARRY-334543; ARRY-543; ASLAN-001; QBT-01; SPS-4370; VAR; Varlitinib tosylateLatest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; ASLAN Pharmaceuticals; National University Hospital (Singapore)
- Class Antineoplastics; Diamines; Oxazoles; Quinazolines; Small molecules; Thiazoles
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Biliary cancer
- Phase II/III Gastric cancer
- Phase II Cholangiocarcinoma; HER2 positive breast cancer
- Phase I/II Liver cancer
- No development reported Solid tumours; Triple negative breast cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in USA (PO)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in Singapore (PO, Tablet)
- 28 Nov 2020 No recent reports of development identified for phase-I development in Biliary-cancer(Combination therapy, Late-stage disease, Metastatic disease) in Japan (PO)